Form 4: Ceribell Director William W. Burke Receives 8,828 Restricted Stock Units

Ceribell, Inc. Director William W. Burke has acquired 8,828 restricted stock units, increasing his direct beneficial ownership in the company.

Summary

• William W. Burke, a Director of Ceribell, Inc. (CBLL), acquired 8,828 shares of Common Stock on June 10, 2025.
• These shares were acquired at a price of $0, indicating they are restricted stock units (RSUs) as per the explanation.
• Following this transaction, Mr. Burke's direct beneficial ownership in Ceribell, Inc. stands at 17,391 shares.
• The transaction was reported in a Statement of Changes in Beneficial Ownership (Form 4) filed with the SEC on June 17, 2025.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally a positive signal, indicating continued alignment of interests between management and shareholders and a commitment to the company's future. It's a routine compensation event, not indicative of major operational changes, hence a moderately positive score.

Positives

• The acquisition of 8,828 restricted stock units by Director William W. Burke at a $0 price signifies a grant, which is a standard form of executive compensation.
• This grant increases Mr. Burke's direct beneficial ownership to 17,391 shares, further aligning his financial interests with those of the company's shareholders.
• RSU grants typically include vesting schedules, which incentivize long-term commitment and performance from the director.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports a routine compensation-related equity grant.

Risks

• The document itself does not detail specific risks, as it is a transaction report. General risks associated with RSU grants include potential minor dilution if not managed properly, though the amount here is relatively small.

Future Outlook

The document is a transaction report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing reflects a routine insider equity grant, a common practice across industries to compensate and incentivize directors and executives. It aligns the director's financial interests with the long-term performance of Ceribell, Inc., a practice widely adopted in the healthcare technology or medical device sector where Ceribell likely operates.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) at a $0 price to a director is a standard compensation practice in publicly traded companies, particularly in the technology and healthcare sectors.
• Companies like Medtronic (MDT), Intuitive Surgical (ISRG), or smaller biotech firms frequently use RSU grants to attract and retain talent and align management incentives with shareholder value.
• The specific number of units (8,828) would need to be compared against Ceribell's overall compensation philosophy and peer group compensation data to assess if it's within typical ranges for a director of a company of Ceribell's size and stage, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, as the value of the RSUs is tied to the company's stock performance. This can be seen as a positive for long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The restricted stock units are subject to a vesting schedule, which will determine when they convert into fully owned shares, though the specific schedule is not detailed in this filing.

Key Dates

Recommendation

Keywords

Ceribell Inc., CBLL, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU, Director compensation, Beneficial ownership, Equity grant